Loading...

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified int...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Calcif Tissue Int
Main Authors: Hagino, Hiroshi, Yoshida, Seitaro, Hashimoto, Junko, Matsunaga, Masayuki, Tobinai, Masato, Nakamura, Toshitaka
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2014
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239781/
https://ncbi.nlm.nih.gov/pubmed/25377907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-014-9927-7
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!